Extension of Time to File SOU

PTO- 1581

Approved for use through 03/31/2024. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1581

Approved for use through 03/31/2024. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

SOU Extension Request
(15 U.S.C. Section 1051(d))

To the Commissioner for Trademarks:

MARK: CTX130 (see, http://uspto.report/TM/88296767/mark.png)
SERIAL NUMBER: 88296767

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: CRISPR Therapeutics AG, having an address of
      Baarerstrasse 14
      ZUG V8, 6300
      Switzerland
      Email: XXXX
Proposed: CRISPR Therapeutics AG, having an address of
      Baarerstrasse 14
      ZUG V8, 6300
      Switzerland
      Phone:
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 11/12/2019.

For International Class 005:
Current identification: Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


For International Class 042:
Current identification: Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, namely, pharmaceutical research and development

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the third extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension request: product or service research or development

Correspondence Information (current):
      Tiffany D. Gehrke
      PRIMARY EMAIL FOR CORRESPONDENCE: docket@marshallip.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): tgehrke@marshallip.com

Correspondence Information (proposed):
      Tiffany D. Gehrke
      PRIMARY EMAIL FOR CORRESPONDENCE: docket@marshallip.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): tgehrke@marshallip.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $250 will be submitted with the form, representing payment for 2 classes.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /Anders Kassow/      Date Signed: 04/14/2021
Signatory's Name: Anders Kassow
Signatory's Position: Executive Director, Intellectual Property
Signature method: Sent to third party for signature

PAYMENT: 88296767
PAYMENT DATE: 04/14/2021

Serial Number: 88296767
Internet Transmission Date: Wed Apr 14 12:00:34 ET 2021
TEAS Stamp: USPTO/ESU-XX.XXX.XX.XXX-2021041412003417
0315-88296767-7703eb1282fb4863187fb79dd2
78e5c01439a218648c56cec94ff51fd9c01944b-
CC-00300791-20210413124950729916